In many cases of C3 glomerulopathy, the deposition of C3 in glomeruli leads to subsequent activation of C5 and there is considerable interest in the possibility of using the anti-C5 antibody eculizumab for treatment. This evidence concerns the gene C3 and complement 3 glomerulopathy.